Seeking Signal Detection in Schizophrenia Trials
Schizophrenia drug development faces rising placebo response rates and diminishing effect sizes, with nearly half of Phase III CNS studies failing to demonstrate treatment group separation. How can sponsors protect signal detection and improve trial outcomes?
In episode four of our "Clinical Viewpoints" video series, Executive Advisor and prolific schizophrenia researcher Dr. David Daniel reveals how patterns of aberrant data variability including erratic ratings and unusual score fluctuations consistently predict increased placebo response and diminished signal detection across both acute and negative symptom schizophrenia trials.
Key insights covered:
- How erratic rating patterns systematically increase placebo response and decrease drug-placebo separation
- Quality indicators that flag sites and raters at risk for compromising endpoint data
- Practical strategies for implementing targeted interventions during trial conduct
- Leveraging blinded analytics to identify and address quality concerns before they impact outcomes
Watch below to discover proven, actionable trial management strategies to protect your schizophrenia endpoints and increase confidence in regulatory submissions.
